Results 201 to 210 of about 293,042 (263)

Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets. [PDF]

Front Cardiovasc Med
Hassan A, Yosry Emam A, Samir M, Sobhy K, Abd El Nabi I, Ali H, Thabet M, Elghazoly A, Thabet N, Elguindy A.   +9 more
europepmc   +1 more source

Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD. [PDF]

Circ Res
Saum KL, Pennathur S, Kanter JE.
europepmc   +1 more source

Cost-Utility Analysis of High-Intensity Statins; Atorvastatin 40 and 80 mg versus Rosuvastatin 20 mg from Egyptian Public Payer's Perspective: A Markov Model. [PDF]

Int J Prev Med
Ibrahim A, ElSherbiny D, Alhussaini MA, Masroja A, Anan I.   +4 more
europepmc   +1 more source

Why does LDL-C follow a different paradigm from other endocrine-metabolic diseases in cardiovascular prevention? [PDF]

Front Endocrinol (Lausanne)
Sánchez-Quesada JL, Pérez A.
europepmc   +1 more source

Unmasking residual cardiovascular risk: the paradoxical interaction between remnant cholesterol and calculated LDL-C in a tertiary-care cohort. [PDF]

Lipids Health Dis
Gözgöz H, Kabul S, Gürsoy Doruk Ö.
europepmc   +1 more source